MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Tag: DLL3

DLL3

Latest news

Tag

news

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib

This case report details successful management of RET-altered medullary thyroid carcinoma using tarlatamab after selpercatinib progression, highlighting modified dosing to mitigate toxicities and achieve complete response.

Jun 11, 2026
Diabetes & Endocrinology

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib

A 64-year-old man with RET-altered medullary thyroid carcinoma who progressed on selpercatinib achieved complete response after modified dosing of tarlatamab with manageable CRS/ICANS.

Jun 10, 2026
news

Obrixtamig (BI 764532): A Promising DLL3/CD3 T-Cell Engager in Heavily Pretreated DLL3-Positive Neuroendocrine Cancers

Phase I trial of obrixtamig, a DLL3/CD3 T-cell engager, shows tolerability and encouraging efficacy in heavily pretreated patients with DLL3-positive SCLC and neuroendocrine carcinomas, supporting further development.

Sep 21, 2025

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story